DOI: https://doi.org/10.52540/2074-9457.2022.1.68

УДК 618.2:577.164.17

Скачать статью

 

М. Р. Конорев

РОЛЬ ФОЛИЕВОЙ КИСЛОТЫ ПРИ ПЛАНИРОВАНИИ И В ПЕРИОД БЕРЕМЕННОСТИ

Витебский государственный ордена Дружбы народов медицинский университет, г. Витебск, Республика Беларусь

 

Статья посвящена роли фолиевой, или птероилглутаминовой, кислоты (витами-на Вс) в период преконцепции и беременности. Фолиевая кислота участвует в пуриновом обмене, который определяет нормальное развитие эмбриона. Тератогенный эффект при дефиците витамина Вс проявляется в нарушении развития нервной трубки. Показано, что последствия дефицита фолиевой кислоты в период беременности проявляются в нарушении физического (замедление роста у детей) и психического развития новорожденных, а также в снижении устойчивости к инфекционным заболеваниям. Витамин Вс также играет важную роль в профилактике возникновения дефектов развития нервной трубки. В связи с большой протективной ролью фолиевой кислоты для формирования здорового генофонда человека является актуальным назначение фолиевой кислоты перед зачатием и в первые 28дней беременности, когда отмечается наиболее низкое содержание витамина Вс в организме женщины. Рекомендуемая суточная доза фолиевой кислоты в период преконцепции, беременности и лактации составляет 400 мкг в день.

На фармацевтическом рынке Республики Беларусь присутствует лекарственный препарат, содержащий в таблетированной форме 0,4 мг фолиевой кислоты, производства ОАО «Борисовский завод медицинских препаратов». Фолиевая кислота 0,4мг (BORIMED) – единственный на рынке Республики Беларусь монопрепарат безрецептурного отпуска из рекомендованных ВОЗ в дозе 0,4 мг/сутки в период преконцепции и во время беременности в качестве первичной профилактики врожденных пороков развития нервной трубки новорожденных.

 

Ключевые слова:

фолиевая кислота, преконцепция, беременность.

 

 

SUMMARY

R. Konorev

THE ROLE OF FOLIC ACID IN PLANNING AND IN THE PERIODOF PREGNANCY

Vitebsk State Order of Peoples' Friendship Medical University, Vitebsk, The Republic of Belarus

The article is devoted to the role of folic or pteroylglutamic acid (vitamin Bc) during preconception and pregnancy. Folic acid is involved in purine metabolism which determines normal development of the embryo. Teratogenic effect in vitamin Bc deficiency is presented in the disorder of the neural tube development. Сonsequences of folic acid deficiency during pregnancy are shown to be presented in the physical (growth retardation in children) and mental disorder in the development of newborns as well as in the depletion in resistance to infectious diseases. Vitamin Bc also plays an important role in the prevention of the neural tube defects. In connection with a great protective role of folic acid for the formation of a healthy human genepool, it is important to prescribe folic acid before conception and in the first 28 days of pregnancy when the lowest content of vitamin Bc in a woman's body is noted. Recommended daily dose of folic acid is 400 mcg/day during preconception, pregnancy and lactation.

On the pharmaceutical market of the Republic of Belarus there is a medicinal product containing 0,4 mg of folic acid in a tablet form manufactured by BORIMED. Folic acid 0,4 mg (BORIMED) is the only over-the-counter single monodrug on the market of the Republic of Belarus recommended by WHO at a dose of 0,4 mg/day during preconception and pregnancy as a primary prevention of congenital neural tube defects in newborns.

Keywords:

folic acid, preconception, pregnancy.

 

ЛИТЕРАТУРА:

  1. Folate: Fact Sheet for Health Professionals [Electronic resource] // National Institutes of Health. – Mode of access: https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/. – Date of access: 27.02.2022.
  2. Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine / S. J. Weinstein [et al.] // Cancer epidemiology, biomarkers & prevention. – 2003. – Vol. 12, N11, pt. 1. – P. 1271–1272.
  3. Botez, M. I. Folate deficiency and neurological disorders in adults / M. I. Botez // Med. hypotheses.– 1976. – Vol. 2, N 4. – P. 135–140.
  4. Pubchem [Electronic resource]. – Mode of access: https://pubchem. ncbi.nlm.nih.gov/» https://pubchem.ncbi.nlm.nih.gov/. – Date of access: 28.02.2022.
  5. Hoffbrand, A. V. The history of folic acid / A. V. Hoffbrand, D. G. Weir // Brit. j. haemato-logy. – 2001. – Vol. 113, N 3. – P. 579–89.
  6. Wills, L. Treatment of “pernicious anaemia of pregnancy” and “tropical anaemia” with special reference to yeast extract as curative agent / L. Wills // Brit. med. j. – 1931. – Vol. 1, N 3676. – P. 1059–1064.
  7. Mitchell, H. K. The concentration of «folic acid» / H. K. Mitchell, E. E. Snell, R. J. Williams // J.of the Amer. chem. soc. – 1941. – Vol. 63. – P. 2284.
  8. Synthesis of a compound identical with the L. casei factor isolated from liver / R. B. Angier [et al.]// Science. – 1945. – Vol. 102, N 2644. – P. 227–228.
  9. Hanes, F. M. Diagnostic criteria and resistance to therapy in the sprue syndrome / F. M. Hanes // The Amer. j. of the med. sciences. – 1942. – Vol. 204, N 3. – P. 436–443.
  10. Davidson, L. S. P. Folic acid in the treatment of sprue syndrome / L. S. P. Davidson, R. H. Girdwood, E. M. Innes // Lancet. – 1947. – Vol. 1, N 6451. – P. 511–515.
  11. Canadian Nutrient File (Dietitician of Canada); 2010 [Electronic resource]. – Mode of access: www.hc-sc.gc.ca/fn-an/nutrition/fiche-nutri-data/index-eng.php» www.hc-sc.gc.ca/fn-an/nutrition/fiche-nutri-data/index-eng.php/. – Date of access: 28.02.2022.
  12. Carmel, R. Folic acid / R. Carmel // Modern nutrition in health and disease / ed.: M. Shils [et al.].– Baltimore: Lippincott Williams & Wilkins, 2005. – P. 470–481.
  13. Bailey, L. B. Folate / L. B. Bailey, J. F. Gregory 3rd. // Present Knowledge in Nutrition / ed.: B. A. Bowman, R. M. Russell. – 9th ed. – Washington: International Life Sciences Institute, 2006. – P. 278–301.
  14. Biomarkers of folate status in NHANES: a roundtable summary / E. A. Yetley [et al.] // The Amer. j. of clinical nutrition. – 2011. – Vol. 94, N 1. – P. 303S–312S.
  15. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline / Institute of Medicine, Food and Nutrition Board.– Washington: National Academy Press, 1998.
  16. Green, R. Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies / R. Green // The Amer. j. of clinical nutrition. – 2011. – Vol. 94, N 2. – P. 666S–672S.
  17. Duthie, S. J. Folic acid deficiency and cancer: mechanisms of DNA instability / S. J. Duthie // Brit. med. bull. – 1999. – Vol. 55, N 3. – P. 578–592.
  18. DNA N-glycosidases: properties of uracil-DNA glycosidase from Escherichia coli / T. Lindahl [etal.] // The j. of biol. chemistry. – 1977. – Vol. 252, N 10. – P. 3286–3294.
  19. Goulian, M. Methotrexate-induced misincorporation of uracil in DNA / M. Goulian, B. Bleile, B.Y. Tseng // Proc. of the Nat. Acad. of Sciences of the USA. – 1980. – Vol. 77, N 4. – P. 1956–1960.
  20. Reidy, J. A. Folate and deoxyuridine sensitive chromatid breakage may result from DNA repair during G2 / J. A. Reidy // Mutation research. – 1987. – Vol. 192, N 3. – P. 217–219.
  21. Reidy, J. A. Role of deoxyuridine incorporation and DNA repair in the expression of human chromosomal fragile sites / J. A. Reidy // Mutat. Res. – 1988. – Vol. 200, N 1/2. – P. 215–220.
  22. Studies on the hypomethylation of c-myc, cHa-ras oncogenes and histopathological changes in human gastric carcinoma / J. Y. Fang [et al.] // J. of gastroenterology and hepatology. – 1996. – Vol. 11, N 11. – P. 1079–1082.
  23. Feinberg, A. P. Hypomethylation distinguishes genes of some human cancers from their normal counterparts / A. P. Feinberg, B. Vogelstein // Nature. – 1983. – Vol. 301. – P. 89–92.
  24. Ghoshal, A. K. The induction of liver cancer by dietary deficiency of choline and methionine without added carcinogens / A. K. Ghoshal, E. Farber // Carcinogenesis. – 1984. – Vol. 5, N 10. – P. 1367–1370.
  25. Шиффман, Ф. Дж. Патофизиология крови / Ф. Дж. Шиффман ; пер. с англ. Н. Б. Серебряной, В. И. Соловьева. – Москва: Бином, 2001. – 448 с.
  26. Methylenetetrahydrofolate reductase mutation and neural tube defects / P. N. Kirke [et al.] // Lancet. – 1996. – Vol. 348, N 9033. – P. 1037–1038.
  27. Lucas, A. A programming by early nutrition in man / A. Lucas // Ciba Found. symp. – 1991. – Vol.156. – P. 38–50.
  28. Фофанова, И. Ю. Роль витаминов и микроэлементов в сохранении репродуктивного здоровья / И. Ю. Фофанова // Гинекология. – 2005. – Т. 7, № 4. – С. 244–249.
  29. Березов, Т. Т. Биологическая химия / Т. Т. Березов, Б. Ф. Коровкин ; под ред. С. С. Дебова.– Москва: Медицина, 1990. – 528 с.
  30. Лифляндский, В. Г. Лечебные свойства пищевых продуктов / В. Г. Лифляндский, В. В. Закревский, М. Н. Андронов. – Москва: Терра, 1999. – 544 с.
  31. Пилат, Т. Л. Биологически активные добавки к пище (теория, производство, применение) / Т. Л. Пилат, А. А. Иванов. – Москва: Аввалон, 2002. – 710 с.
  32. Prevalence of neural tube defects in 20 regions of Europe and the impact of prenatal diagnosis, 1980-1986. EUROCAT Working Group // J. of Epidemiology and community Health. – 1991. – Vol. 45, N1.– P. 52–58.
  33. Elwood, J. M. Epidemiology and control of the neural tube defects / J. M. Elwood, J.Little, J.H.Elwood. – Oxford: Oxford University Press, 1992. – 944 p.
  34. Влияние циннаризина и алвитила на мозговой кровоток и высшую нервную деятельность на модели хронической церебральной ишемии / А. А. Никонов [и др.] // Журн. неврологии и психиатрии им. С. С. Корсакова. – 2004. – № 1. – С. 52–53.
  35. Ramakrishna, T. Vitamins and brain development / T. Ramakrishna // Physiol. research. – 1999. – Vol. 48, suppl. 3. – P. 175–187.
  36. Preconception folate and vitamin В(6) status and clinical spontaneous abortion in Chinese women/ A. G. Ronnenberg [et al.] // Obstetrics and gynecology. – 2002. – Vol. 100, N 1. – P. 107–113.
  37. Fowler, B. Disorders of homocysteine metabolism / B. Fowler // J. of inherited metabolic disease.– 1997. – Vol. 20, N 2. – P. 270–285.
  38. Hages, М. Praevention von Neuralrohrdefekten (NRD) durch perikonzeptionelle Folsaeuregaben. Eine Darstellung des aktuellen Forschungsstandes / M. Hages, B. Thorand, R. Prinz-Langenohl // Geburtshilfe und Frauenheilkunde. – 1996. – Vol. 56. – P. M59–M65.
  39. Громова, О. А. Витамины и минералы у беременных и кормящих женщин: обучающие программы ЮНЕСКО / О. А. Громова. – Москва, 2007. – 140 с.
  40. Imdad, A. The effect of folic acid, protein energy and multiple micronutrient supplements in pregnancy on stillbirths / A. Imdad, M. Y. Yakoob, Z. A. Bhutta // BMC public health. – 2011. – Vol. 11, suppl3.– P. S4.
  41. Grosse, S. D. Folic acid supplementation and neural tube defect recurrence prevention / S.D.Grosse, J. S. Collins // Birth defects research. Part A, Clinical and molecular teratology. – 2007. – Vol.79, N11. – P. 737–742.
  42. Ахмина, Н. И. Антенатальное формирование здоровья ребенка / Н. И. Ахмина. – Москва: МЕДпресс-информ, 2005. – 208 с.
  43. Prevention of neural tube defects: Results of the Medical Research Council vitamin study / N. Wald [et al.] // Lancet. – 1991. – Vol.338, N8760. – P. 131–137.
  44. Folic acid and the prevention of disease [Electronic resource]: rep. of the Comm. on Med. Aspects of Food and Nutrition Policy. – London: The Stationery Office, 2000. – Mode of access: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/743522/Folic_Acid_and_the_Prevention_of_Disease__2000_.pdf. – Date of access: 28.02.2022
  45. Czeizel, A. E. Prevention of Developmental Abnormalities with Particular Emphasis of Primary Prevention / A. E. Czeizel // Tsitologiia i genetika. – 2002. – Vol. 36, N5. – P. 58–72.
  46. Czeizel, A. E. Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities / A. E. Czeizel, M. Dobo, P. Vargha // Birth defects research. Part A, Clinical and molecular teratology. – 2004. – Vol. 70, N11. – P. 853–861.
  47. Опыт применения комплексного препарата «Элевит Пронаталь» у беременных с заболеваниями щитовидной железы / Н. М. Подзолкова [и др.] // Гинекология. – 2004. – Т.6, №3. – C. 147–150.
  48. Шехтман, М. М. Железодефицитная анемия и беременность / М. М. Шехтман // Гинекология. – 2004. – Т.6, №4. – С. 204–210.
  49. Шехтман, М. М. Железодефицитная анемия у беременных и ее лечение / М. М. Шехтман, А.П. Никонов // Гинекология. – 2000. – Т.2, №5. – С.156–160.
  50. Жученко, Л. А. Профилактика врожденных пороков развития у плода и новорожденного: пособие для врачей / Л. А. Жученко. – Москва: Москов. обл. науч.-исследоват. ин-т акушерства и гинекологии, 2001. – 33 с.
  51. Food standards: amendments of the standards of identity for enriched grain products to require addition of folic acid; Clarification / United States Department Health and Human Services, Food and Drug Administration // Federal Register. – 1996. – Vol.61. – P.8781–8807.
  52. Folic acid supplements in pregnancy and birth outcome: re-analysis of a large randomised controlled trial and update of Cochrane review / D. H. Charles [et al.] // Paediatric and perinatal epidemiology. – 2005. – Vol.9, N2. – P. 112–124.
  53. Ребров, В. Г. Витамины и микроэлементы / В. Г. Ребров, О. А. Громова. – Москва: АЛЕВ-В, 2003. – 670 с.
  54. Pimentel, J. Current issues on epileptic women / J. Pimentel // Current pharmaceutical des. – 2000.– Vol.6, N8. – P. 865–872.
  55. Patterns and predictors of folic acid supplement use among pregnant women: the Norwegian Mother and Child Cohort Study / R. M. Nilsen [et al.] // The Amer. j. of clinical nutrition. – 2006. – Vol. 84, N5. – P. 1134–1141.
  56. Пекарев, О. Г. Результаты использования Элевита Пронаталя у беременных / О. Г. Пекарев// Гинекология. – 2006. – Т.8, № . – C. 46–49.
  57. Об утверждении клинического протокола «Медицинское наблюдение и оказание медицинской помощи женщинам в акушерстве и гинекологии» : постановление М-ва здравоохранения Респ. Беларусь, 19 февр. 2018г.,№ 17 // Национальный правовой Интернет-портал Республики Беларусь. – Режим доступа: https://pravo.by/document/?guid=12551&p0=W21833049p&p1=1. – Дата доступа: 28.02.2022.
  58. Об установлении перечня основных лекарственных средств [Электронный ресурс]: постановление М-ва здравоохранения Респ. Беларусь, 16 июля 2007 г., № 65: с изм. и доп.: постановление М-ва здравоохранения Респ. Беларусь, 18 нояб. 2020 г., № 106 // Бизнес-Инфо / Проф. правовые системы. – Минск, 2021.
  59. Об установлении перечня лекарственных средств белорусского (российского) производства, обязательных для наличия в аптеках [Электронный ресурс]: постановление М-ва здравоохранения Респ. Беларусь, 10 дек. 2018 г., № 92: с изм. и доп.: постановление М-ва здравоохранения Респ. Беларусь, 30 марта 2021 г., № 26 // Бизнес-Инфо / Проф. правовые системы. – Минск, 2021.
  60. Об установлении перечня лекарственных препаратов, реализуемых без рецепта врача [Электронный ресурс]: постановление М-ва здравоохранения Респ. Беларусь, 10 апр. 2019 г., № 27: с изм. и доп.: постановление М-ва здравоохранения Респ. Беларусь, 8 нояб. 2021 г., № 120 // Национальный правовой интернет-портал Республики Беларусь. – Режим доступа: https://pravo.by/document/?guid=12551&p0=W21934175&p1=1. – Дата доступа: 28.02.2022.
  61. Государственный реестр лекарственных средств Республики Беларусь [Электронный ресурс] / Центр экспертиз и испытаний в здравоохранении. – Режим доступа: https://www.rceth.by/Refbank/reestr_lekarstvennih_sredstv. – Дата доступа: 28.02.2022.
  62. Tabletka.by [Электронный ресурс]. – Режим доступа: https://tabletka.by/. – Дата доступа: 01.03.2022.

REFERENCES

  1. Folate: Fact Sheet for Health Professionals [Electronic resource] // National Institutes of Health. – Mode of access: https://ods.od.nih.gov/factsheets/Folate-HealthProfessional/. – Date of access: 27.02.2022.
  2. Weinstein SJ, Hartman TJ, Stolzenberg-Solomon R, Pietinen P, Barrett MJ, Taylor PR et al. Null association between prostate cancer and serum folate, vitamin B(6), vitamin B(12), and homocysteine. Cancer Epidemiol Biomarkers Prev. 2003;12(11 Pt 1):1271–2
  3. Botez MI. Folate deficiency and neurological disorders in adults. Med Hypotheses. 1976;2(4):135–40. doi: 10.1016/0306-9877(76)90068-2
  4. Pubchem [Electronic resource]. Mode of access: https://pubchem. ncbi.nlm.nih.gov/» https://pubchem.ncbi.nlm.nih.gov/. Date of access: 28.02.2022
  5. Hoffbrand AV, Weir DG. The history of folic acid. Br J Haematol. 2001;113(3):579–89. doi: 10.1046/j.1365-2141.2001.02822.x
  6. Wills L. Treatment of “pernicious anaemia of pregnancy” and “tropical anaemia” with special reference to yeast extract as curative agent. Br Med J. 1931;1(3676):1059–64
  7. Mitchell HK, Snell EE, Williams RJ. The concentration of «folic acid». J Am Chem Soc. 1941;63:2284
  8. Angier RB, Boothe JH, Hutchings BL, Mowat JH, Semb J, Stokstad EL et al. Synthesis of a compound identical with the L. casei factor isolated from liver. Science. 1945;102(2644):227–8. doi: 10.1126/science.102.2644.227
  9. Hanes FM. Diagnostic criteria and resistance to therapy in the sprue syndrome. Am J Med Sci. 1942;204(3):436–43
  10. Davidson LSP, Girdwood RH, Innes EM. Folic acid in the treatment of sprue syndrome. Lancet. 1947;1(6451):511–5. doi: 10.1016/s0140-6736(47)91626-7
  11. Canadian Nutrient File (Dietitician of Canada); 2010 [Electronic resource]. Mode of access: www.hc-sc.gc.ca/fn-an/nutrition/fiche-nutri-data/index-eng.php» www.hc-sc.gc.ca/fn-an/nutrition/fiche-nutri-data/index-eng.php/. Date of access: 28.02.2022
  12. Carmel R. Folic acid. In: Shils M, Shike M, Ross A, Caballero B, Cousins R. editors. Modern nutrition in health and disease. Baltimore, USA: Lippincott Williams & Wilkins; 2005. p. 470-81
  13. Bailey LB, Gregory JF 3rd. Folate. In: Bowman BA, Russell RM, editors. Present Knowledge in Nutritionl. 9th ed. Washington, USA: International Life Sciences Institute; 2006. p. 278–301
  14. Yetley EA, Pfeiffer CM, Phinney KW, Fazili Z, Lacher DA, Bailey RL et al. Biomarkers of folate status in NHANES: a roundtable summary. Am J Clin Nutr. 2011;94(1):303S–12S. doi: 10.3945/ajcn.111.013011
  15. Institute of Medicine, Food and Nutrition Board. Dietary reference intakes for thiamin, riboflavin, niacin, vitamin B6, folate, vitamin B12, pantothenic acid, biotin, and choline.Washington, USA: National Academy Press; 1998. doi: 10.17226/6015
  16. Green R. Indicators for assessing folate and vitamin B-12 status and for monitoring the efficacy of intervention strategies. Am J Clin Nutr. 2011;94(2):666S-72S. doi: 10.3945/ajcn.110.009613
  17. Duthie SJ. Folic acid deficiency and cancer: mechanisms of DNA instability. Br Med Bull. 1999;55(3):578–92. doi: 10.1258/0007142991902646
  18. Lindahl T, Ljungqust S, Siegert W, Nyberg B, Sperens B. DNA N-glycosidases: properties of uracil-DNA glycosidase from Escherichia coli. J Biol Chem. 1977;252(10):3286-94
  19. Goulian M, Bleile B, Tseng BY. Methotrexate-induced misincorporation of uracil in DNA. Proc Natl Acad Sci USA. 1980;77(4):1956–60. doi: 10.1073/pnas.77.4.1956
  20. Reidy JA. Folate and deoxyuridine sensitive chromatid breakage may result from DNA repair during G2. Mutat Res. 1987;192(3):217–9. doi: 10.1016/0165-7992(87)90059-5
  21. Reidy JA. Role of deoxyuridine incorporation and DNA repair in the expression of human chromosomal fragile sites. Mutat Res. 1988;200(1-2):215–20. doi: 10.1016/0027-5107(88)90085-1
  22. Fang JY, Zhu SS, Xiao SD, Jiang SJ, Shi Y, Chen XY et al. Studies on the hypomethylation of c-myc, cHa-ras oncogenes and histopathological changes in human gastric carcinoma. J Gastroenterol Hepatol. 1996;11(11):1079–82. doi: 10.1111/j.1440-1746.1996.tb00040.x.
  23. Feinberg AP, Vogelstein B. Hypomethylation distinguishes genes of some human cancers from their normal counterparts. Nature. 1983;301:89–92. doi: 10.1038/301089a0
  24. Ghoshal AK, Farber E. The induction of liver cancer by dietary deficiency of choline and methionine without added carcinogens. Carcinogenesis. 1984;5(10):1367–70. doi: 10.1093/carcin/5.10.1367
  25. Shiffman FDzh. Pathophysiology of blood. Serebrianaia NB, Solov'ev VI, perevodchiki. Moskva, RF: Binom; 2001. 448 s. (In Russ.)
  26. Kirke PN, Mills JL, Whitehead AS, Molloy A, Scott JM. Methylenetetrahydrofolate reductase mutation and neural tube defects. Lancet. 1996;348(9033):1037–8. doi: 10.1016/S0140-6736(05)64971-9
  27. Lucas A. Programming by early nutrition in man. Ciba Found Symp. 1991;156:38–50
  28. Fofanova IIu. The role of vitamins and microelements in maintaining reproductive health. Ginekologiia. 2005;7(4):244–9. (In Russ.)
  29. Berezov TT, Korovkin BF. Biological chemistry. Debov SS, redaktor. Moskva, RF: Meditsina; 1990. 528 s. (In Russ.)
  30. Lifliandskii VG, Zakrevskii VV, Andronov MN. Medicinal properties of foods. Moskva, RF: Terra; 1999. 544 s. (In Russ.)
  31. Pilat TL, Ivanov AA. Biologically active food supplements (theory, production, application). Moskva, RF: Avvalon; 2002. 710 s. (In Russ.)
  32. Prevalence of neural tube defects in 20 regions of Europe and the impact of prenatal diagnosis, 1980-1986. EUROCAT Working Group. J Epidemiol Community Health. 1991;45(1):52–8. doi: 10.1136/jech.45.1.52
  33. Elwood JM, Little J, Elwood JH. Epidemiology and control of the neural tube defects. Oxford, Great Britain: Oxford University Press; 1992. 944 p
  34. Nikonov AA, Gromova OA, Sadin AV. Zhidomorov NIu, Grishina TR, Borzunov MP i drugie. The effect of cinnarizine and alvitil on cerebral blood flow and higher nervous activity in a model of chronic cerebral ischemia. Zhurn nevrologii i psikhiatrii im Korsakova SS. 2004;(1):52–3. (In Russ.)
  35. Ramakrishna T. Vitamins and brain development. Physiol Res. 1999;48 Suppl 3:175–87
  36. Ronnenberg AG, Goldman MB, Chen D, Aitken IW, Willett WC, Selhub J et al. Preconception folate and vitamin В(6) status and clinical spontaneous abortion in Chinese women. Obstet Gynecol. 2002;100(1):107–13. doi: 10.1016/s0029-7844(02)01978-6
  37. Fowler B. Disorders of homocysteine metabolism. J Inherit Metab Dis. 1997;20(2):270–85. doi: 10.1023/a:1005369109055
  38. Hages М, Thorand B, Prinz-Langenohl R. Praevention von Neuralrohrdefekten (NRD) durch perikonzeptionelle Folsaeuregaben. Eine Darstellung des aktuellen Forschungsstandes. Geburtshilfe Frauenheilkd. 1996;56:M59–M65
  39. Gromova OA. Vitamins and minerals in pregnant and lactating women: obuchaiushchie programmy IuNESKO. Moskva, RF; 2007. 140 s. (In Russ.)
  40. Imdad A, Yakoob MY, Bhutta ZA. The effect of folic acid, protein energy and multiple micronutrient supplements in pregnancy on stillbirths. BMC Public Health. 2011;11 Suppl 3:S4. doi: 10.1186/1471-2458-11-S3-S4
  41. Grosse SD, Collins JS. Folic acid supplementation and neural tube defect recurrence prevention. Birth Defects Res A Clin Mol Teratol. 2007;79(11):737–42. doi: 10.1002/bdra.20394
  42. Akhmina NI. Antenatal formation of a child's health. Moskva, RF: MEDpress-inform; 2005. 208 s. (In Russ.)
  43. Wald N, Sneddon J, Densem J, Frost Ch, Stone R. Prevention of neural tube defects: Results of the Medical Research Council vitamin study. Lancet. 1991;338(8760):131-7. doi: 10.1016/0140-6736(91)90133-A
  44. Folic acid and the prevention of disease [Electronic resource]: report of the Committee on Medical Aspects of Food and Nutrition Policy. London, Great Britain: The Stationery Office; 2000. Mode of access: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/743522/Folic_Acid_and_the_Prevention_of_Disease__2000_.pdf. Date of access: 28.02.2022
  45. Czeizel AE. Prevention of developmental abnormalities with particular emphasis of primary prevention. Tsitol Genet. 2002;36(5):58–72
  46. Czeizel AE, Dobo M, Vargha P. Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities. Birth Defects Res A Clin Mol Teratol. 2004;70(11):853–61. doi: 10.1002/bdra.20086
  47. Podzolkova NM, Skvortsova MIu, Nesterova AA, Nazarova SV, Evdokimova IuA, Al'-Saied M. Experience in the use of the complex drug "Elevit Pronatal" in pregnant women with thyroid diseases. Ginekologiia. 2004;6(3):147–50. (In Russ.)
  48. Shekhtman MM. Iron deficiency anemia and pregnancy. Ginekologiia. 2004;6(4):204–10. (In Russ.)
  49. Shekhtman MM, Nikonov AP. Iron deficiency anemia in pregnant women and its treatment. Ginekologiia. 2000;2(5):156–60. (In Russ.)
  50. Zhuchenko LA. Prevention of congenital malformations in the fetus and newborn: posobie dlia vrachei. Moskva, RF: Moskov obl nauch-issledovat in-t akusherstva i ginekologii; 2001. 33 s. (In Russ.)
  51. United States Department Health and Human Services, Food and Drug Administration. Food standards: amendments of the standards of identity for enriched grain products to require addition of folic acid; Clarification . Federal Register. 1996;61:8781–807
  52. Charles DH, Ness AR, Campbell D, Smith GD, Whitley E, Hall MH. Folic acid supplements in pregnancy and birth outcome: re-analysis of a large randomised controlled trial and update of Cochrane review. Paediatr Perinat Epidemiol. 2005;19(2):112–24. doi: https://doi.org/10.1111/j.1365-3016.2005.00633.x
  53. Rebrov VG, Gromova OA. Vitamins and trace elements. Moskva, RF: ALEV-V; 2003. 670 s. (In Russ.)
  54. Pimentel J. Current issues on epileptic women. Curr Pharm Des. 2000;6(8):865–72. doi: 10.2174/1381612003400263
  55. Nilsen RM, Vollset SE, Gjessing HK, Magnus P, Meltzer HM, Haugen M et al. Patterns and predictors of folic acid supplement use among pregnant women: the Norwegian Mother and Child Cohort Study. Am J Clin Nutr. 2006;84(5):1134–41. doi: 10.1093/ajcn/84.5.1134
  56. Pekarev OG. The results of using Elevit Pronatal in pregnant women. Ginekologiia. 2006;8(1):46-9. (In Russ.)
  57. On approval of the clinical protocol “Medical supervision and provision of medical care to women in obstetrics and gynecology” : postanovlenie M-va zdravookhraneniia Resp Belarus’ 19 fevr 2018 g № 17. Natsional’nyi pravovoi Internet-portal Respubliki Belarus’. Rezhim dostupa: https://pravo.by/document/?guid=12551&p0=W21833049p&p1=1. Data dostupa: 28.02.2022.
  58. On establishing a list of essential medicines [Elektronnyi resurs]: postanovlenie M-va zdravookhraneniia Resp Belarus’ 16 iiulia 2007 g № 65: s izm i dop: postanovlenie M-va zdravookhraneniia Resp Belarus’ 18 noiab 2020 g № 106. V: Professional’nye pravovye sistemy. Biznes-Info. Minsk, RB; 2021. (In Russ.)
  59. On the establishment of a list of medicines of Belarusian (Russian) production, mandatory for availability in pharmacies [Elektronnyi resurs]: postanovlenie M-va zdravookhraneniia Resp Belarus' 10 dek 2018 g № 92: s izm i dop: postanovlenie M-va zdravookhraneniia Resp Belarus' 30 marta 2021 g № 26. V: Professional'nye pravovye sistemy. Biznes-Info. Minsk, RB; 2021. (In Russ.)
  60. On the establishment of a list of drugs sold without a doctor's prescription [Elektronnyi resurs]: postanovlenie M-va zdravookhraneniia Resp Belarus' 10 apr 2019 g № 27 s izm i dop: postanovlenie M-va zdravookhraneniia Resp Belarus' 8 noiab. 2021 g № 120. Natsional'nyi pravovoi internet-portal Respubliki Belarus'. Rezhim dostupa: https://pravo.by/document/?guid=12551&p0=W21934175&p1=1. Data dostupa: 28.02.2022. (In Russ.)
  61. Tsentr ekspertiz i ispytanii v zdravookhranenii. State Register of Medicinal Products of the Republic of Belarus [Elektronnyi resurs]. Rezhim dostupa: https://www.rceth.by/Refbank/reestr_lekarstvennih_sredstv. Data dostupa: 28.02.2022. (In Russ.)
  62. Tablet.by [Elektronnyi resurs]. Rezhim dostupa: https://tabletka.by/. Data dostupa: 01.03.2022. (In Russ.)

Адрес для корреспонденции:

210009, Республика Беларусь,

г. Витебск, пр. Фрунзе, 27,

УО «Витебский государственный ордена

Дружбы народов медицинский университет»,

кафедра общей и клинической фармакологии

с курсом ФПК и ПК,

тел. раб.: 8 (0212) 58-13-87,

Конорев М.Р.

Поступила    02.03.2022 г.